Fig. 7

a–t Overall survival (OS) and benefit of tamoxifen in quartiles of GEX signatures (Q1–Q4). Kaplan–Meier plots for each quartile of selected GEX signatures stratified by treatment (Tam vs. control) in patients with ER+/HER2− tumors; a–d AR, e–h ESR1, i–l FOXA1, m–p Mast cells and q–t PGR. HRs with 95% CI are shown for the full-time follow-up and the first 10 years. CI confidence interval, ER estrogen receptor, GEX gene expression, HER2 human epidermal growth factor receptor 2, HR hazard ratio, OS overall survival, Q quartile, Tam tamoxifen